8-K Announcements
6Material company update
Apr 9, 2026·SEC
Material company update
Feb 27, 2026·SEC
Material company update
Jan 13, 2026·SEC
Treace Medical Concepts, Inc.(TMCI)Earnings, Financials & Key Ratios
TMCI•NASDAQ
$1.93
$123M mkt cap·Price updated May 6, 2026
AboutTreace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.Show more
- Revenue$213M+1.6%
- EBITDA-$54M-14.6%
- Net Income-$59M-5.8%
- EPS (Diluted)-0.93-3.3%
- Gross Margin79.81%-0.7%
- EBITDA Margin-25.46%-12.8%
- Operating Margin-25.46%+4.3%
- Net Margin-27.74%-4.2%
- ROE-58.94%-32.6%
- ROIC-31.03%-36.1%
- Debt/Equity0.16-74.1%
TMCI Key Insights
Treace Medical Concepts, Inc. (TMCI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 30.0%
- ✓Trading at only 1.4x book value
- ✓Efficient asset utilization: 1.1x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TMCI Price & Volume
Treace Medical Concepts, Inc. (TMCI) stock price & volume — 10-year historical chart
Loading chart...
TMCI Growth Metrics
Treace Medical Concepts, Inc. (TMCI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years29.96%
3 Years14.46%
TTM1.59%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5.85%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-4.68%
Return on Capital
10 Years-21.83%
5 Years-28.05%
3 Years-30.31%
Last Year-31.66%
TMCI Recent Earnings
Treace Medical Concepts, Inc. (TMCI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 27, 2026EPS
$0.12
Est $0.15
+21.0%
Revenue
$63M
Est $62M
+1.1%
Q4 2025
Nov 6, 2025EPS
$0.26
Est $0.28
+7.1%
Revenue
$50M
Est $62M
-18.7%
Q3 2025
Aug 7, 2025EPS
$0.28
Est $0.29
+3.4%
Revenue
$47M
Est $50M
-4.9%
Q2 2025
May 8, 2025EPS
$0.25
Est $0.31
+19.4%
Revenue
$53M
Est $50M
+6.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 27, 2026 | $0.12vs $0.15+21.0% | $63Mvs $62M+1.1% |
| Q4 2025 | Nov 6, 2025 | $0.26vs $0.28+7.1% | $50Mvs $62M-18.7% |
| Q3 2025 | Aug 7, 2025 | $0.28vs $0.29+3.4% | $47Mvs $50M-4.9% |
| Q2 2025 | May 8, 2025 | $0.25vs $0.31+19.4% | $53Mvs $50M+6.2% |
Based on last 12 quarters of dataView full earnings history →
TMCI Peer Comparison
Treace Medical Concepts, Inc. (TMCI) competitors in Orthopedics, spine, and sports medicine — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ANGO | 459.4M | 11.05 | -13.31 | -3.76% | -9.02% | -15.71% | ||
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATEC | 1.06B | 6.99 | -7.28 | 24.95% | -21.07% | -141.88% | 17.21 | |
 OSUR | 215.9M | 3.00 | -3.19 | -38.1% | -61.93% | -19.46% | 0.04 | |
 PRCT | 1.41B | 24.80 | -14.42 | 37.22% | -31.82% | -27.7% | 0.14 | |
 CNMD | 1.15B | 37.32 | 24.72 | 5.16% | 4% | 5.4% | 0.81 | |
 MMSI | 3.68B | 61.63 | 28.93 | 11.66% | 9.03% | 8.95% | 0.57 | |
 IRTC | 3.87B | 117.70 | -84.68 | 26.24% | -3.53% | -20.6% | 4.79 |
Compare TMCI vs Peers
Treace Medical Concepts, Inc. (TMCI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TMCI Income Statement
Treace Medical Concepts, Inc. (TMCI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 39.42M | 57.37M | 94.42M | 141.84M | 187.12M | 209.36M | 212.69M |
| Revenue Growth % | - | 45.54% | 64.59% | 50.22% | 31.92% | 11.88% | 1.59% |
| Cost of Goods Sold | 7.63M | 12.47M | 16.89M | 27.52M | 35.18M | 41.09M | 42.94M |
| COGS % of Revenue | 19.36% | 21.74% | 17.89% | 19.4% | 18.8% | 19.63% | 20.19% |
| Gross Profit | 31.79M▲ 0% | 44.9M▲ 41.2% | 77.53M▲ 72.7% | 114.31M▲ 47.4% | 151.94M▲ 32.9% | 168.26M▲ 10.7% | 169.75M▲ 0.9% |
| Gross Margin % | 80.64% | 78.26% | 82.11% | 80.6% | 81.2% | 80.37% | 79.81% |
| Gross Profit Growth % | - | 41.25% | 72.69% | 47.44% | 32.91% | 10.75% | 0.88% |
| Operating Expenses | 35.32M | 44.04M | 94.04M | 149.16M | 203.37M | 223.95M | 223.91M |
| OpEx % of Revenue | 89.61% | 76.77% | 99.6% | 105.16% | 108.68% | 106.97% | 105.27% |
| Selling, General & Admin | 30.25M | 38.19M | 83.84M | 137.57M | 187.93M | 203.36M | 203.62M |
| SG&A % of Revenue | 76.75% | 66.58% | 88.79% | 96.99% | 100.43% | 97.14% | 95.74% |
| Research & Development | 5.07M | 5.85M | 10.2M | 13.58M | 15.44M | 20.59M | 20.28M |
| R&D % of Revenue | 12.86% | 10.19% | 10.81% | 9.58% | 8.25% | 9.83% | 9.54% |
| Other Operating Expenses | 0 | 0 | 0 | -1.99M | 0 | 0 | 0 |
| Operating Income | -3.54M▲ 0% | 855K▲ 124.2% | -16.51M▼ 2031.0% | -34.84M▼ 111.0% | -51.43M▼ 47.6% | -55.69M▼ 8.3% | -54.15M▲ 2.8% |
| Operating Margin % | -8.97% | 1.49% | -17.49% | -24.57% | -27.48% | -26.6% | -25.46% |
| Operating Income Growth % | - | 124.19% | -2030.99% | -111.05% | -47.59% | -8.28% | 2.75% |
| EBITDA | -2.74M | 2.06M | -15.82M | -32.71M | -46.08M | -47.27M | -54.15M |
| EBITDA Margin % | -6.96% | 3.6% | -16.76% | -23.06% | -24.62% | -22.58% | -25.46% |
| EBITDA Growth % | - | 175.31% | -866.34% | -106.7% | -40.86% | -2.59% | -14.57% |
| D&A (Non-Cash Add-back) | 793K | 1.21M | 685K | 2.13M | 5.35M | 8.42M | 0 |
| EBIT | -3.42M | 855K | -16.49M | -38.42M | -44.36M | -50.49M | 0 |
| Net Interest Income | -730K | -4.52M | -4.04M | -3.08M | 1.56M | -379K | 0 |
| Interest Income | 111K | 0 | 18K | 1.31M | 6.73M | 4.88M | 2.78M |
| Interest Expense | 841K | 4.52M | 4.06M | 4.4M | 5.17M | 5.26M | -5.32M |
| Other Income/Expense | -730K | -4.52M | -4.04M | -7.97M | 1.9M | -55K | -4.85M |
| Pretax Income | -4.26M▲ 0% | -3.67M▲ 14.0% | -20.55M▼ 460.3% | -42.81M▼ 108.3% | -49.53M▼ 15.7% | -55.74M▼ 12.6% | -59M▼ 5.8% |
| Pretax Margin % | -10.82% | -6.39% | -21.77% | -30.19% | -26.47% | -26.63% | -27.74% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.26M▲ 0% | -3.67M▲ 14.0% | -20.55M▼ 460.3% | -42.81M▼ 108.3% | -49.53M▼ 15.7% | -55.74M▼ 12.6% | -59M▼ 5.8% |
| Net Margin % | -10.82% | -6.39% | -21.77% | -30.19% | -26.47% | -26.63% | -27.74% |
| Net Income Growth % | - | 14% | -460.31% | -108.33% | -15.68% | -12.55% | -5.85% |
| Net Income (Continuing) | -4.26M | -3.67M | -20.55M | -42.81M | -49.53M | -55.74M | -59M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.10▲ 0% | -0.08▲ 15.6% | -0.38▼ 351.3% | -0.77▼ 102.6% | -0.81▼ 5.2% | -0.90▼ 11.1% | -0.93▼ 3.3% |
| EPS Growth % | - | 15.63% | -351.31% | -102.63% | -5.19% | -11.11% | -3.33% |
| EPS (Basic) | -0.10 | -0.08 | -0.38 | -0.77 | -0.81 | -0.90 | -0.93 |
| Diluted Shares Outstanding | 51.17M | 51.17M | 54.18M | 55.28M | 60.85M | 62.11M | 63.27M |
| Basic Shares Outstanding | 51.17M | 51.17M | 54.18M | 55.28M | 60.85M | 62.11M | 63.27M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
TMCI Balance Sheet
Treace Medical Concepts, Inc. (TMCI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 28.57M | 40.98M | 137.97M | 133.4M | 198.36M | 161.4M | 132.05M |
| Cash & Short-Term Investments | 12.14M | 18.08M | 105.83M | 81.25M | 123.2M | 75.68M | 48.37M |
| Cash Only | 12.14M | 18.08M | 105.83M | 19.47M | 12.98M | 11.35M | 10.71M |
| Short-Term Investments | 0 | 0 | 0 | 61.78M | 110.22M | 64.33M | 37.66M |
| Accounts Receivable | 10.41M | 14.49M | 18.57M | 29.2M | 38.06M | 40.8M | 42.16M |
| Days Sales Outstanding | 96.41 | 92.17 | 71.78 | 75.13 | 74.25 | 71.14 | 72.34 |
| Inventory | 5.56M | 7.82M | 10.56M | 19.33M | 29.25M | 39.26M | 36.03M |
| Days Inventory Outstanding | 266.04 | 228.89 | 228.25 | 256.35 | 303.41 | 348.67 | 306.29 |
| Other Current Assets | 0 | 0 | 0 | 3.62M | 7.85M | 5.67M | 5.5M |
| Total Non-Current Assets | 1.15M | 829K | 2.85M | 25.62M | 53.55M | 55.69M | 58.53M |
| Property, Plant & Equipment | 1.15M | 829K | 2.85M | 25.48M | 31.56M | 34.4M | 37.37M |
| Fixed Asset Turnover | 34.39x | 69.20x | 33.14x | 5.57x | 5.93x | 6.09x | 5.69x |
| Goodwill | 0 | 0 | 0 | 0 | 12.81M | 12.81M | 12.81M |
| Intangible Assets | 0 | 0 | 0 | 0 | 9.03M | 8.07M | 7.13M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 146K | 146K | 407K | 1.22M |
| Total Assets | 29.72M▲ 0% | 41.81M▲ 40.7% | 140.82M▲ 236.8% | 159.02M▲ 12.9% | 251.91M▲ 58.4% | 217.09M▼ 13.8% | 190.58M▼ 12.2% |
| Asset Turnover | 1.33x | 1.37x | 0.67x | 0.89x | 0.74x | 0.96x | 1.12x |
| Asset Growth % | - | 40.69% | 236.84% | 12.93% | 58.41% | -13.82% | -12.21% |
| Total Current Liabilities | 7.33M | 11.6M | 18.21M | 30.25M | 45.03M | 34.92M | 30.64M |
| Accounts Payable | 931K | 2.27M | 4.06M | 8.67M | 11.84M | 10.52M | 6.73M |
| Days Payables Outstanding | 44.53 | 66.3 | 87.66 | 114.95 | 122.79 | 93.46 | 57.18 |
| Short-Term Debt | 0 | 1.79M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 1K | 0 | 7.67M | 24.25M | 2.22M | 30.64M |
| Current Ratio | 3.90x | 3.53x | 7.58x | 4.41x | 4.40x | 4.62x | 4.31x |
| Quick Ratio | 3.14x | 2.86x | 7.00x | 3.77x | 3.76x | 3.50x | 3.13x |
| Cash Conversion Cycle | 317.91 | 254.77 | 212.37 | 216.53 | 254.87 | 326.35 | 321.45 |
| Total Non-Current Liabilities | 19.22M | 29.43M | 29.54M | 68.25M | 68.94M | 69.28M | 72.61M |
| Long-Term Debt | 19.22M | 29.19M | 29.36M | 52.71M | 53.01M | 53.31M | 13.98M |
| Capital Lease Obligations | 0 | 0 | 0 | 15.54M | 15.89M | 15.93M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 244K | 173K | 0 | 37K | 37K | 58.63M |
| Total Liabilities | 26.55M | 41.03M | 47.75M | 98.5M | 113.97M | 104.2M | 103.25M |
| Total Debt | 19.22M | 30.98M | 29.36M | 68.59M | 70.3M | 69.65M | 13.98M |
| Net Debt | 7.08M | 12.9M | -76.47M | 49.12M | 57.32M | 58.3M | 3.27M |
| Debt / Equity | 6.08x | 39.92x | 0.32x | 1.13x | 0.51x | 0.62x | 0.16x |
| Debt / EBITDA | - | 15.00x | - | - | - | - | - |
| Net Debt / EBITDA | - | 6.25x | - | - | - | - | - |
| Interest Coverage | -4.20x | 0.19x | -4.07x | -7.92x | -9.95x | -10.60x | - |
| Total Equity | 3.16M▲ 0% | 776K▼ 75.5% | 93.07M▲ 11893.9% | 60.53M▼ 35.0% | 137.94M▲ 127.9% | 112.89M▼ 18.2% | 87.33M▼ 22.6% |
| Equity Growth % | - | -75.45% | 11893.94% | -34.97% | 127.89% | -18.16% | -22.64% |
| Book Value per Share | 0.06 | 0.02 | 1.72 | 1.10 | 2.27 | 1.82 | 1.38 |
| Total Shareholders' Equity | 3.16M | 776K | 93.07M | 60.53M | 137.94M | 112.89M | 87.33M |
| Common Stock | 28K | 28K | 45K | 55K | 62K | 62K | 64K |
| Retained Earnings | -17.69M | -21.35M | -41.91M | -84.72M | -134.25M | -189.99M | -248.99M |
| Treasury Stock | 0 | 0 | 0 | 0 | -13K | -281K | 0 |
| Accumulated OCI | 0 | 0 | 0 | -27K | 163K | 97K | 72K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TMCI Cash Flow Statement
Treace Medical Concepts, Inc. (TMCI) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.67M | -4.49M | -17.19M | -30.65M | -34.58M | -37.17M | -15.97M |
| Operating CF Margin % | -19.47% | -7.83% | -18.21% | -21.61% | -18.48% | -17.75% | -7.51% |
| Operating CF Growth % | - | 41.43% | -282.58% | -78.26% | -12.81% | -7.5% | 57.03% |
| Net Income | -4.26M | -3.67M | -20.55M | -42.81M | -49.53M | -55.74M | -59M |
| Depreciation & Amortization | 793K | 1.21M | 685K | 2.13M | 5.35M | 8.42M | 10.5M |
| Stock-Based Compensation | 815K | 919K | 3.41M | 8.11M | 17.35M | 30.6M | 33.82M |
| Deferred Taxes | 0 | 2.14M | 419K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 292K | 221K | 176K | 7.73M | 1.99M | 4.99M | -1.29M |
| Working Capital Changes | -5.31M | -5.32M | -1.33M | -5.81M | -9.74M | -25.43M | 0 |
| Change in Receivables | -6.02M | -4.29M | -4.23M | -11.04M | -9.3M | -5.69M | -2.09M |
| Change in Inventory | -2.81M | -3.4M | -3.09M | -8.77M | -9.85M | -10.01M | 3.22M |
| Change in Payables | -236K | 1.33M | 1.79M | 4.61M | 3.17M | -1.31M | -3.8M |
| Cash from Investing | -1.21M | -1.07M | -2.71M | -76.52M | -81.3M | 35.38M | 13.25M |
| Capital Expenditures | -1.21M | -1.07M | -2.71M | -14.84M | -11.46M | -11.59M | -13.52M |
| CapEx % of Revenue | 3.07% | 1.86% | 2.86% | 10.46% | 6.12% | 5.54% | 6.36% |
| Acquisitions | 0 | 0 | 0 | 61.68M | -20M | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -61.68M | 0 | 0 | 0 |
| Cash from Financing | 19.74M | 11.5M | 107.65M | 20.81M | 109.38M | 160K | 2.08M |
| Debt Issued (Net) | 20M | 11.32M | -1.79M | 19.61M | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 364K | 1000K | 1000K | 1000K | 428K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -261K | -179K | 0 | -989K | -13K | -268K | 2.08M |
| Net Change in Cash | 10.86M▲ 0% | 5.94M▼ 45.3% | 87.75M▲ 1377.3% | -86.36M▼ 198.4% | -6.49M▲ 92.5% | -1.63M▲ 74.9% | -642K▲ 60.7% |
| Free Cash Flow | -8.88M▲ 0% | -5.56M▲ 37.4% | -19.9M▼ 257.7% | -45.49M▼ 128.6% | -46.03M▼ 1.2% | -48.76M▼ 5.9% | -29.49M▲ 39.5% |
| FCF Margin % | -22.54% | -9.7% | -21.07% | -32.07% | -24.6% | -23.29% | -13.86% |
| FCF Growth % | - | 37.38% | -257.68% | -128.6% | -1.2% | -5.92% | 39.53% |
| FCF per Share | -0.17 | -0.11 | -0.37 | -0.82 | -0.76 | -0.79 | -0.47 |
| FCF Conversion (FCF/Net Income) | 1.80x | 1.23x | 0.84x | 0.72x | 0.70x | 0.67x | 0.27x |
| Interest Paid | 739K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TMCI Key Ratios
Treace Medical Concepts, Inc. (TMCI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -134.93% | -186.33% | -43.8% | -55.75% | -49.91% | -44.45% | -58.94% |
| Return on Invested Capital (ROIC) | - | 5.36% | -81.79% | -41.4% | -25.3% | -22.79% | -31.03% |
| Gross Margin | 80.64% | 78.26% | 82.11% | 80.6% | 81.2% | 80.37% | 79.81% |
| Net Margin | -10.82% | -6.39% | -21.77% | -30.19% | -26.47% | -26.63% | -27.74% |
| Debt / Equity | 6.08x | 39.92x | 0.32x | 1.13x | 0.51x | 0.62x | 0.16x |
| Interest Coverage | -4.20x | 0.19x | -4.07x | -7.92x | -9.95x | -10.60x | - |
| FCF Conversion | 1.80x | 1.23x | 0.84x | 0.72x | 0.70x | 0.67x | 0.27x |
| Revenue Growth | - | 45.54% | 64.59% | 50.22% | 31.92% | 11.88% | 1.59% |
TMCI SEC Filings & Documents
Treace Medical Concepts, Inc. (TMCI) SEC filings — annual & quarterly reports (10-K, 10-Q)
TMCI Frequently Asked Questions
Treace Medical Concepts, Inc. (TMCI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Treace Medical Concepts, Inc. (TMCI) reported $212.7M in revenue for fiscal year 2025. This represents a 440% increase from $39.4M in 2019.
Treace Medical Concepts, Inc. (TMCI) grew revenue by 1.6% over the past year. Growth has been modest.
Treace Medical Concepts, Inc. (TMCI) reported a net loss of $59.0M for fiscal year 2025.
Dividend & Returns
Treace Medical Concepts, Inc. (TMCI) has a return on equity (ROE) of -58.9%. Negative ROE indicates the company is unprofitable.
Treace Medical Concepts, Inc. (TMCI) had negative free cash flow of $29.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More TMCI
Treace Medical Concepts, Inc. (TMCI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates